Mountain Group Capital

Mountain Group News

Latest News

G1 Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2017 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that it has been added to the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes, effective after market close on September 15, 2017, as part of Russell’s quarterly addition of companies with recent initial public offerings. The Russell 2000 Index measures the performance of the small-cap segment of the U.S….

Myomo, Inc. Obtains CE Mark Approval for MyoPro®

Enables Company to Start Providing Devices in Europe

CAMBRIDGE, Mass., July 31, 2017 – Myomo, Inc. (NYSE MKT: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it has obtained CE Mark approval for commercial sale of its next-generation MyoPro myoelectric arm orthosis across the European Economic Area (EEA). The CE Mark indicates MyoPro complies with the essential requirements of relevant EU legislation and has achieved quality system certification. MyoPro is the only…

G1 Therapeutics Appoints Sir Andrew Witty to Board of Directors

RESEARCH TRIANGLE PARK, N.C., July 13, 2017 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced the appointment of Sir Andrew Witty to its board of directors. “We are thrilled to welcome Andrew to our board of directors,” said Mark Velleca, MD, PhD, Chief Executive Officer of G1 Therapeutics. “Andrew led and oversaw the development, commercialization, and global market access for several leading pharmaceutical products at…

Biotech company ORIG3N nabs $20 mln

BOSTON, June 27, 2017 – ORIG3N, Inc., a Boston-based biomedical research company, has announced the addition of Byron Smith to its Board of Directors and Spectrum Health Ventures (SHV) to its investor syndicate. The announcements come on the heels of the close of ORIG3N’s latest round of funding. ORIG3N has raised over $30 million in capital to date since it was founded in 2014. Byron Smith brings decades of industry…

Myomo, Inc. Completes Historic Initial Public Offering

First company to go public on the NYSE MKT under JOBS Act Regulation A+

Cambridge, MA., June 9, 2017 – Myomo, Inc. (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced the completion of its initial public offering (IPO) under SEC Regulation A+, raising $5.0 Million through the sale of 665,498 shares of its common stock at a price to the public of $7.50 per share. The Company also closed on a simultaneous private sale of investment units comprised of restricted…

G1 Therapeutics to Present Clinical Data on CDK4/6 Inhibitor Trilaciclib at the 2017 American Society of Clinical Oncology Annual Meeting

RESEARCH TRIANGLE PARK, N.C., May 30, 2017 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a study of its lead CDK4/6 inhibitor trilaciclib as a first-line combination treatment in patients with extensive stage small-cell lung cancer (SCLC) will be presented in a poster session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, to be…

FUTURE Local Coverage Determination for MolDX: DecisionDxUM (Uveal Melanoma) (L37033)

Uveal melanoma is a rare cancer, affecting ~1600-1700 patients per year in the United States, but it is the most common intraocular cancer in adults. Uveal melanoma arises in the middle layer of the eye, the uvea tract, which consists of the iris, ciliary body, and choroid. Eyesparing radiation (brachytherapy or proton beam therapy) is the most common treatment approach, but approximately 10% of patients will undergo enucleation due to…

G1 Therapeutics Announces Pricing of Initial Public Offering

RESEARCH TRIANGLE PARK, N.C., May 16, 2017 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc., a clinical-stage oncology company, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $105,000,000. In addition, G1 Therapeutics has granted the underwriters a 30-day option to purchase up to 1,050,000 additional shares of its common stock at…

NeuroTronik Announces $23.1 Million Series B Preferred Stock Financing

Funding to advance NeuroTronik CANS Therapy™ to improve the treatment of Acute Heart Failure in the Hospital Pre-clinical and clinical experience has been highly-encouraging as to the promise of the therapy

Dublin, Ireland and Durham, North Carolina, USA – 18 April 2017 – NeuroTronik Limited and NeuroTronik, Inc. today announced closing on a $23.1 million Series B Preferred Stock Financing, tranched in line with project plan milestones. The funding was led by Boston Scientific Group, plc. Other major investors include Hatteras Venture Partners, Synergy Life Science Partners, Lord Baltimore Investment Partners, Mountain Group Capital, and Sovereign’s Capital. The investor group also…

G1 Therapeutics Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting

RESEARCH TRIANGLE PARK, NC – March 29, 2017 – G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that it will present preclinical data on trilaciclib, G1T38, and G1T48 at the 2017 American Association for Cancer Research (AACR) Annual Meeting, to be held April 1-5 in Washington, DC. Details on the two poster presentations are as follows: Title: Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and…

Next Page →